Published On: Wed, Oct 19th, 2016

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) Analyst Review


A number of investment brokers have recently updated their price targets on shares of Isis Pharmaceuticals, Inc. (NASDAQ:ISIS).

Most recent broker ratings

12/18/2015 – Isis Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Piper Jaffray.

12/03/2015 – Wells Fargo began new coverage on Isis Pharmaceuticals, Inc. giving the company a “outperform” rating.

11/18/2015 – Goldman Sachs began new coverage on Isis Pharmaceuticals, Inc. giving the company a “neutral” rating. They now have a USD 65 price target on the stock.

11/10/2015 – Isis Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Needham & Company. They now have a USD 88 price target on the stock.

11/09/2015 – Isis Pharmaceuticals, Inc. had its “equal weight” rating reiterated by analysts at Barclays. They now have a USD 65 price target on the stock.

06/22/2015 – Isis Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Deutsche Bank. They now have a USD 78 price target on the stock.

06/11/2015 – Isis Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 95 price target on the stock.

06/08/2015 – Isis Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at JP Morgan. They now have a USD 68 price target on the stock.

05/08/2015 – Isis Pharmaceuticals, Inc. was upgraded to “buy” by analysts at Zacks. They now have a USD 68 price target on the stock.

04/20/2015 – Isis Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Cowen.

03/17/2015 – Janney Montgomery Scott began new coverage on Isis Pharmaceuticals, Inc. giving the company a “neutral” rating.

03/02/2015 – Isis Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Brean Capital.

03/02/2015 – Isis Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Stifel Nicolaus. They now have a USD 66 price target on the stock.

01/20/2015 – Isis Pharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at Leerink Swann. They now have a USD 68 price target on the stock.

12/08/2014 – Isis Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Laidlaw. They now have a USD 65 price target on the stock.

The share price of Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) was up +0.00% during the last day of trading, with a day high of 0.00. 0 shares were traded during the last session.

The stock’s 50 day moving average is 58.93 and its 200 day moving average is 53.82.Isis Pharmaceuticals, Inc. has a 52-week low of 37.38 and a 52-week high of 77.80.

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company’s subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.